Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma

BACKGROUND: Phase IIb clinical trial with isatuximab (Isa)-lenalidomide (Len)-dexamethasone (Dex) showed an improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (RRMM), but the efficacy varied by patient. Antibody-dependent cell-mediated cytotoxicity (ADC...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Haibo, Martin, Thomas G, Marra, John, Kong, Denice, Keats, Jonathon, Macé, Sandrine, Chiron, Marielle, Wolf, Jeffrey L, Venstrom, Jeffrey M, Rajalingam, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287616/
https://www.ncbi.nlm.nih.gov/pubmed/34272304
http://dx.doi.org/10.1136/jitc-2021-002958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287616/
https://www.ncbi.nlm.nih.gov/pubmed/34272304
http://dx.doi.org/10.1136/jitc-2021-002958

Ejemplares similares